D-galactose-induced toxicity associated senescence mitigated by alpinate oxyphyllae fructus fortified adipose-derived mesenchymal stem cells.
Hung-Jen LinSamiraj RameshYung-Ming ChangChuan-Te TsaiChin-Chuan TsaiMarthandam Asokan ShibuShanmugam TamilselviB MahalakshmiWei-Wen KuoChih-Yang HuangPublished in: Environmental toxicology (2020)
This study addresses the effect of D-galactose-induced toxicity associated senescence mitigated by alpinate oxyphyllae fructus (AOF; Alpinia oxyphylla Miq) extracts fortified with adipose-derived mesenchymal stem cells (ADMSCs) in rats. Male 18 week-old Wistar Kyoto (WKY) rats were used in this study. We analyzed cardiac fibrosis by Masson's trichrome staining. The tissue sections were dyed using hematoxylin and eosin (H&E). Tissue sections were stained for the restoration of Nrf2 expression in treatment groups by immunohistochemistry. Immunohistochemistry and western blotting analysis showed that AOF with ADMSCs could significantly reduce aging-induced oxidative stress in D-galactose-induced aging rat hearts by inducing Nrf2 pathway. Reduction in ROS resulted in the suppression of inflammatory signals (p-NF-κB and IL-6). Histopathological studies were showed an increased interstitium and collagen accumulation in aging-induced heart sections. However, AOF and ADMSCs treated hearts were recovered from cardiac remodeling. Furthermore, hypertrophy and fibrosis associated markers were also significantly reduced (P < .05) in treatment groups. We speculate that ADMSCs might activate certain paracrine factors, which could target the upstream activator of aging associated cardiac complications and AOF might provide homing for these stem cells.
Keyphrases
- oxidative stress
- diabetic rats
- high glucose
- stem cells
- dna damage
- endothelial cells
- left ventricular
- drug induced
- heart failure
- poor prognosis
- south africa
- immune response
- mesenchymal stem cells
- cell death
- inflammatory response
- combination therapy
- atrial fibrillation
- nuclear factor
- newly diagnosed
- bone marrow
- replacement therapy
- binding protein
- flow cytometry